Grafts of Fetal Dopamine Neurons Survive and Improve Motor Function in Parkinson's Disease

  • Olle Lindvall
    Department of Neurology, University Hospital, S-221 85 Lund, Sweden.
  • Patrik Brundin
    Department of Medical Cell Research, Biskopsgatan 5, S-223 62 Lund, Sweden.
  • Håkan Widner
    Department of Neurology, University Hospital, S-221 85 Lund, Sweden.
  • Stig Rehncrona
    Department of Neurosurgery, University Hospital, S-221 85 Lund, Sweden.
  • Björn Gustavii
    Department of Gynecology, University Hospital, S-221 85 Lund, Sweden.
  • Richard Frackowiak
    MRC Cyclotron Unit, Hamersmith Hospital, London W12 OHS, United Kingdom.
  • Klaus L. Leenders
    Paul Scherrer Institute, Switzerland.
  • Guy Sawle
    MRC Cyclotron Unit, Hamersmith Hospital, London W12 OHS, United Kingdom.
  • John C. Rothwell
    MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, The National Hospital, Queen Square, London WCIN 3BG, United Kingdom.
  • C. David Marsden
    MRC Human Movement and Balance Unit and University Department of Clinical Neurology, Institute of Neurology, The National Hospital, Queen Square, London WCIN 3BG, United Kingdom.
  • Marsden Björklund
    Department of Medical Cell Research, Biskopsgatan 5, S-223 62 Lund, Sweden.

抄録

<jats:p> Neural transplantation can restore striatal dopaminergic neurotransmission in animal models of Parkinson's disease. It has now been shown that mesencephalic dopamine neurons, obtained from human fetuses of 8 to 9 weeks gestational age, can survive in the human brain and produce marked and sustained symptomatic relief in a patient severely affected with idiopathic Parkinson's disease. The grafts, which were implanted unilaterally into the putamen by stereotactic surgery, restored dopamine synthesis and storage in the grafted area, as assessed by positron emission tomography with 6-L-[ <jats:sup>18</jats:sup> F]fluorodopa. This neurochemical change was accompanied by a therapeutically significant reduction in the patient's severe rigidity and bradykinesia and a marked diminuation of the fluctuations in the patient's condition during optimum medication (the "on-off" phenomenon). The clinical improvement was most marked on the side contralateral to the transplant. </jats:p>

収録刊行物

  • Science

    Science 247 (4942), 574-577, 1990-02-02

    American Association for the Advancement of Science (AAAS)

被引用文献 (23)*注記

もっと見る

キーワード

詳細情報

問題の指摘

ページトップへ